- Home
- LSPD vs JANX Comparison
LSPD vs JANX Comparison
Compare LSPD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSPD
- JANX
- Stock Information
- Founded
- LSPD 2005
- JANX 2017
- Country
- LSPD Canada
- JANX United States
- Employees
- LSPD N/A
- JANX N/A
- Industry
- LSPD
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- LSPD
- JANX Health Care
- Exchange
- LSPD Nasdaq
- JANX Nasdaq
- Market Cap
- LSPD 1.5B
- JANX 1.4B
- IPO Year
- LSPD 2020
- JANX 2021
- Fundamental
- Price
- LSPD $11.81
- JANX $26.18
- Analyst Decision
- LSPD Hold
- JANX Strong Buy
- Analyst Count
- LSPD 13
- JANX 11
- Target Price
- LSPD $13.58
- JANX $76.55
- AVG Volume (30 Days)
- LSPD 547.0K
- JANX 945.2K
- Earning Date
- LSPD 11-06-2025
- JANX 11-06-2025
- Dividend Yield
- LSPD N/A
- JANX N/A
- EPS Growth
- LSPD N/A
- JANX N/A
- EPS
- LSPD N/A
- JANX N/A
- Revenue
- LSPD $1,115,677,000.00
- JANX $439,000.00
- Revenue This Year
- LSPD $14.22
- JANX N/A
- Revenue Next Year
- LSPD $12.03
- JANX $91.66
- P/E Ratio
- LSPD N/A
- JANX N/A
- Revenue Growth
- LSPD 15.46
- JANX N/A
- 52 Week Low
- LSPD $7.34
- JANX $21.73
- 52 Week High
- LSPD $18.96
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- LSPD 51.05
- JANX 54.88
- Support Level
- LSPD $11.01
- JANX $25.62
- Resistance Level
- LSPD $11.74
- JANX $27.70
- Average True Range (ATR)
- LSPD 0.40
- JANX 1.57
- MACD
- LSPD 0.04
- JANX 0.18
- Stochastic Oscillator
- LSPD 74.32
- JANX 57.58
About LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.